These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17873694)

  • 1. Resolution of haloperidol-induced hyperprolactinemia with aripiprazole.
    Lorenz RA; Weinstein B
    J Clin Psychopharmacol; 2007 Oct; 27(5):524-5. PubMed ID: 17873694
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
    Ishitobi M; Kosaka H; Shukunami K; Murata T; Wada Y
    J Clin Psychopharmacol; 2011 Jun; 31(3):400-1; author reply 401. PubMed ID: 21532377
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversal of symptomatic hyperprolactinemia by aripiprazole.
    Wahl R; Ostroff R
    Am J Psychiatry; 2005 Aug; 162(8):1542-3. PubMed ID: 16055781
    [No Abstract]   [Full Text] [Related]  

  • 5. Improvement in tardive dyskinesia with aripiprazole use.
    Witschy JK; Winter AS
    Can J Psychiatry; 2005 Mar; 50(3):188. PubMed ID: 15830835
    [No Abstract]   [Full Text] [Related]  

  • 6. Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot.
    Kantrowitz JT; Srihari VH; Tek C
    J Clin Psychopharmacol; 2007 Oct; 27(5):525-6. PubMed ID: 17873695
    [No Abstract]   [Full Text] [Related]  

  • 7. Bipolar drug development: are we getting closer to the real world?
    Calabrese JR; Kemp DE
    Am J Psychiatry; 2008 Oct; 165(10):1234-6. PubMed ID: 18829876
    [No Abstract]   [Full Text] [Related]  

  • 8. Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole.
    Lian J; Huang XF; Pai N; Deng C
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1157-8; author reply 1159. PubMed ID: 20381569
    [No Abstract]   [Full Text] [Related]  

  • 9. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
    Lee BH; Kim YK; Park SH
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):714-7. PubMed ID: 16571367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with aripiprazole for hyperprolactinemia induced by pituitary microadenoma in a bipolar I disorder patient.
    Chen ST; Hsiao YL
    J Clin Psychopharmacol; 2010 Feb; 30(1):78-80. PubMed ID: 20075655
    [No Abstract]   [Full Text] [Related]  

  • 11. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole reverses paliperidone-induced hyperprolactinemia.
    Basterreche N; Zumárraga M; Arrue A; Olivas O; Dávila W
    Actas Esp Psiquiatr; 2012; 40(5):290-2. PubMed ID: 23076612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
    Chen CK; Huang YS; Ree SC; Hsiao CC
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia.
    Saitis M; Papazisis G; Katsigiannopoulos K; Kouvelas D
    Psychiatry Clin Neurosci; 2008 Oct; 62(5):624. PubMed ID: 18950388
    [No Abstract]   [Full Text] [Related]  

  • 15. Exacerbation of psychotic disorder during pregnancy in the context of medication discontinuation.
    Wakil L; Perea E; Penaskovic K; Stuebe A; Meltzer-Brody S
    Psychosomatics; 2013; 54(3):290-3. PubMed ID: 23218063
    [No Abstract]   [Full Text] [Related]  

  • 16. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia.
    Hoffer ZS; Roth RL; Mathews M
    Psychosomatics; 2009; 50(4):317-24. PubMed ID: 19687170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose manic switch and high-dose antimanic effect and extrapyramidal symptoms by aripiprazole in a single bipolar patient.
    Park YM
    Am J Ther; 2014; 21(6):e218-20. PubMed ID: 23676345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole-induced sialorrhea.
    Praharaj SK; Jana AK; Sinha VK
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):384-5. PubMed ID: 19162120
    [No Abstract]   [Full Text] [Related]  

  • 19. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole.
    Paulzen M; Gründer G
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):149-51. PubMed ID: 16942633
    [No Abstract]   [Full Text] [Related]  

  • 20. Aripiprazole treatment of risperidone-induced hyperprolactinemia.
    Chen JX; Su YA; Wang SL; Bian QT; Liu YH; Wang N; Yang FD; Haile C; Kosten TR; Zhang XY
    J Clin Psychiatry; 2009 Jul; 70(7):1058-9. PubMed ID: 19653986
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.